webinar register page

What's New In: Rare Lung Cancer Subtypes

Jun 16, 2021 03:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Dr. Alexander Drilon, MD
Medical Oncologist @Memorial Sloan Kettering Cancer Centre
Dr. Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for genomic subsets of lung cancer and other solid tumors, including cancers that harbor fusions involving ALK, ROS1, RET, and NTRK1/2/3, and MET exon 14 skipping alterations. He is a recipient of American Society for Clinical Oncology (ASCO)/Conquer Cancer Foundation Career Development and Young Investigator Awards, and grants from the International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation. Dr. Drilon is also a member of the Editorial Board of ASCO University.
Dr. Parneet Cheema, MD, MBiotech, FRCPC
Medical Oncologist @William Osler Health System
Dr. Cheema is a Medical Oncologist and joined Osler in 2017. She is an Assistant Professor with the Department of Medicine at the University of Toronto where she completed her Internal medicine and Medical Oncology training as well as a Master's degree in Biotechnology. She is internationally known as an expert in lung cancer, precision care and immunotherapy and has published numerous research papers and consensus statements. During her time at Osler she advanced the oncology program by leading the redesign of the clinical care model and started programs such as the Osler Cancer Immunotherapy Program and the oral anti-cancer therapy program. As clinical trials lead, she led the growth of clinical trials to become a leader in recruitment and offers patients at Osler state-of-the-art treatments through global collaborations. With her pathology colleagues, her work solidified partnerships that enabled the ability to offer the most advanced genomics for cancer care in Canada.